SAN JUAN CAPISTRANO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the real estate and operations of South Davis Specialty Care a 95-bed skilled nursing operation, located in Bountiful, Utah and Western Peaks Specialty Hospital, a 43-bed long-term acute care hospital (LTACH) located in Bountiful, Utah. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, and the acquisition is effective as of May 1, 2024.
“This acquisition represents a milestone in our organization, as it is the first acquisition of a long-term acute care hospital in our company’s history,” said Barry Port, Ensign's Chief Executive Officer. “We have been carefully reviewing this opportunity for some time and believe we have the leadership in place for a successful transition into a new line of business. We are extremely humbled and honored to have been chosen to continue the legacy of these well-respected operations,” he added.
“We are pleased to combine such a devoted and experienced team to our existing operational and clinical leaders in Utah and we are confident that they are poised to accomplish great things together at these operations,” said Steve Farnsworth, President of Milestone Healthcare LLC, Ensign’s Utah-based subsidiary. “We are excited to work together with our healthcare partners as we strive to provide top-notch care for our patients and their families.”
In separate transactions on the same day, Ensign announced that it acquired six other operations, three of which included real estate assets that were acquired by Standard Bearer. Each of these new facilities will be operated by an Ensign affiliated operator, including the following:
Also, on the same day, Ensign announced that its affiliates acquired the following operations, which will be subject to long-term, triple net leases:
All of these acquisitions are effective as of May 1, 2024 and bring Ensign's growing portfolio to 310 healthcare operations, 29 of which also include senior living operations, across fourteen states. Ensign subsidiaries, including Standard Bearer, own 119 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.
About Ensign™
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 310 healthcare facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.
Contact Information
The Ensign Group, Inc., (949) 487-9500, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$134.59 |
Daily Change: | -0.53 -0.39 |
Daily Volume: | 833,968 |
Market Cap: | US$7.710B |
December 18, 2024 November 13, 2024 November 04, 2024 October 29, 2024 October 24, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB